Doripenem: A new extended-spectrum carbapenem antibiotic

Formulary

Volumn 42, Issue 12, 2007, Pages

  Hagerman, Jennifer K ^a   Knechtel, Stephanie A ^b   Klepser, Michael E ^a  

^a FERRIS STATE UNIVERSITY   (United States)

^b NORTHWESTERN MEMORIAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; CARBAPENEM DERIVATIVE; CILASTATIN; CILASTATIN PLUS IMIPENEM; COTRIMOXAZOLE; DAPTOMYCIN; DORIPENEM; IMIPENEM; LEVOFLOXACIN; LINEZOLID; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; VALPROIC ACID; VANCOMYCIN;

ABDOMINAL INFECTION; ANAEROBIC BACTERIUM; CLINICAL TRIAL; CREATININE CLEARANCE; DIARRHEA; DRUG COST; DRUG SENSITIVITY; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HEADACHE; HOSPITAL INFECTION; HUMAN; MYCOSIS; NAUSEA; NONHUMAN; PHLEBITIS; PNEUMONIA; PRURITUS; PYELONEPHRITIS; RASH; REVIEW; SEIZURE; SIDE EFFECT; SINGLE DRUG DOSE; URINARY TRACT INFECTION;

EID: 38349104602     PISSN: 1082801X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (46)

1. Gaynes R, Edward JR; the National Nosocomial Infections Surveillance System. Overview of nosocomial infections caused by gram-negative bacilli. Clin Infect Dis. 2005;41:848-854.
2. Biedenbach DJ, Moet GJ, Jones RN. Occurrence and antimicrobial resistance pattern comparisons among bloodstream infection isolates from the SENTRY Antimicrobial Surveillance Program (1997-2002). Diagn Microbiol Infect Dis. 2004;50:59-69.
3. Weinstein MP, Towns ML, Quartey SM, et al. The clinical significance of positive blood cultures in the 1990s: A prospective comprehensive evaluation of the microbiology, epidemiology, and outcome of bacteremia and fungemia in adults. Clin Infect Dis. 1997;24:584-602.
4. American Thoracic Society; Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005;171:388-416.
5. New Drug Application submitted for investigational antibiotic doripenem [press release]. Raritan, NJ: Johnson & Johnson; June 6, 2007.
6. Doribax [package insert]. Raritan, NJ: Ortho-McNeil Pharmaceutical Inc; 2007.
7. Norrby SR. Carbapenems. Med Clin North Am. 1995;79:745-759.
8. Mushtaq S, Ge Y, Livermore DM. Comparative activities of doripenem versus isolates, mutants, and transconjugants of Enterobacteriaceae and Acinetobacter spp. with characterized beta-lactamases. Antimicrob Agents Chemother. 2004;48:1313-1319.
9. Jones RN, Sader HS, Fritsche TR. Comparative activity of doripenem and three other carbapenems tested against Gram-negative bacilli with various beta-lactamase resistance mechanisms. Diagn Microbiol Infect Dis. 2005;52:71-74.
10. Tsuji M, Ishii Y, Ohno A, Miyazaki S, Yamaguchi K. In vitro and in vivo antibacterial activities of S-4661, a new carbapenem. Antimicrob Agents Chemother. 1998;42:94-99.
11. Iso Y, Irie T, Nishino Y, Motokawa K, Nishitani Y. A novel 1 beta-methylcarbapenem antibiotic, S-4661. Synthesis and structure-activity relationships of 2-(5-substituted pyrrolidine-3-ylthio)-1 beta- methylcarbapenems. J Antibiot (Tokyo). 1996;49:199-209.
12. Floren LC, Wikler MA, Kilfoil T, Ge Y. A phase 1 open-label controlled study to evaluate the safety, tolerability, and pharmacokinetics (PK) of doripenem (DOR) administered intravenously to subjects with renal impairment. Presented at: 44th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); October 30-November 2, 2004; Washington, DC.
13. Thye D, Kilfoil T, Leighton A, Wikler M. Doripenem: A phase 1 study to evaluate safety, tolerability and pharmacokinetics in a western healthy volunteer population. Abstr Intersci Conf Antimicrob Agents Chemother Intersci Conf Antimicrob Agents Chemother. 2003;43. Abstract A-21.
14. Floren LC, Wikler MA, Kilfoil T, Ge Y. A phase I, double-blind, placebo-controlled study to determine the safety, tolerability, and pharmacokinetics (PK) of prolonged-infusion regimens of doripenem (DOR) in healthy subjects. Presented at: 44th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); October 30-November 2, 2004; Washington, DC.
15. Nakashima M, Kato T, Kimura Y, Sasaki S, Konishi M, Oguma T. S-4661, a new carbapenem: IV Pharmacokinetics in healthy volunteers. Abstr Intersci Conf Antimicrob Agents Chemother Intersci Conf Antimicrob Agents Chemother. 1994;34. Abstract F-39.
16. Nakashima M, Umemura K, Murakami M, Kimura Y, Oguma T. Pharmacokinetics of S-4661, new parenteral carbapenem antibiotic, 1000 mg multiple-dose administration in healthy male volunteers. Abstr Intersci Conf Antimicrob Agents Chemother Intersci Conf Antimicrob Agents Chemother. 1998;38. Abstract F-60.
17. Primaxin [package insert]. Whitehouse Station, NJ: Merck & Co; 2006.
18. Merrem [package insert]. Wilmington, DE: AstraZeneca Corp; 2007.
19. Invanz [package insert]. Whitehouse Station, NJ: Merck & Co; 2007.
20. Shiba K, Nakashima M, Tanimura H, Okada H, Shimada J. Pharmacokinetics and pharmacodynamics of S-4661, new parenteral carbapenem antibiotic. Abstr Intersci Conf Antimicrob Agents Chemother Intersci Conf Antimicrob Agents Chemother. 1997;37. Abstract F-217.
21. Ikawa K, Morikawa N, Urakawa N, Ikeda K, Ohge H, Sueda T. Peritoneal penetration of doripenem after intravenous administration in abdominal-surgery patients. J Antimicrob Chemother. 2007;60:1395-1397.
22. Kim A, Banevicius MA, Nicolau DP. In vivo efficacy of doripenem human-simulated exposures against Pseudomonas aeruginosa. Presented at: 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); September 17-20, 2007; Chicago, IL.
23. Naber K, Redman R, Kotey P, Llorens L, Kaniga K. Intravenous therapy with doripenem versus levofloxacin with an option for oral step-down therapy in the treatment of complicated urinary tract infections and pyelonephritis. Int J Antimicrob Agents. 2007;29(suppl 2):S212. Poster P833.
24. Lucasti C, Jasovich A, Umeh O, Jiang J, Kaniga K. Treatment of complicated intra-abdominal infections: Doripenem versus meropenem. Int J Antimicrob Agents. 2007;29(suppl 2):S212. Poster P834.
25. Rea-Neto A, Niederman M, Lee M, Kaniga K, Prokocimer P, Friedland I. Efficacy and safety of intravenous doripenem vs. piperacillin/tazobactam in nosocomial pneumonia. Presented at: 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); September 17-20, 2007; Chicago, IL.
26. Solomkin J, Umeh O, Jiang J, Kaniga K, Friedland I. Doripenem versus meropenem with an option for oral step-down therapy in the treatment of complicated intra-abdominal infections. Presented at: 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); September 17-20, 2007; Chicago, IL.
27. Chastre J, Wunderink R, Prokocimer P, Lee M, Kaniga K, Friedland I. Efficacy and safety of doripenem versus imipenem for ventilator-associated pneumonia. Presented at: 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); September 17-20, 2007; Chicago, IL.
28. Bhavnani SM, Hammel JP, Cirincione BB, Wikler MA, Ambrose PG. Use of pharmacokinetic-pharmacodynamic target attainment analyses to support phase 2 and 3 dosing strategies for doripenem. Antimicrob Agents Chemother. 2005;49:3944-3947.
29. Fritsche TR, Stilwell MG, Jones RN. Antimicrobial activity of doripenem (S-4661): A global surveillance report (2003). Clin Microbiol Infect. 2005;11:974-984.
30. Wexler HM, Engel AE, Glass D, Li C. In vitro activities of doripenem and comparator agents against 364 anaerobic clinical isolates. Antimicrob Agents Chemother. 2005;49:4413-4417.
31. Jones RN, Huynh HK, Biedenbach DJ, Fritsche TR, Sader HS. Doripenem (S-4661), a novel carbapenem: Comparative activity against contemporary pathogens including bactericidal action and preliminary in vitro methods evaluations. J Antimicrob Chemother. 2004;54:144-154.
32. Bell JM, Fritsche TR, Jones RN, Turnidge JD. Doripenem activity tested against gram-negative pathogens in the Asia-Pacific (APAC) region: Report from the SENTRY Antimicrobial Surveillance Program (2006). Presented at: 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); September 17-20, 2007; Chicago, IL.
33. Goldstein EJC, Citron DM, Merriam CV, Warren YA, Tyrrell KL, Fernandez HT. In vitro activity of doripenem against aerobic and anaerobic bacteria isolated from infected diabetic foot wounds. Presented at: 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); September 17-20, 2007; Chicago, IL.
34. Pillar CM, Aranza-Torres MK, Shah D, Sahm DF. Analysis of doripenem activity, relative to other carbapenems, against target gram-negative pathogens isolated from specific infection sites. Presented at: 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); September 17-20, 2007; Chicago, IL.
35. Jones RN, Huynh HK, Biedenbach DJ. Activities of doripenem (S-4661) against drug-resistant clinical pathogens. Antimicrob Agents Chemother. 2004;48:3136-3140.
36. Traczewski MM, Brown SD. In vitro activity of doripenem against Pseudomonas aeruginosa and Burkholderia cepacia isolates from both cystic fibrosis and non-cystic fibrosis patients. Antimicrob Agents Chemother. 2006;50:819-821.
37. Chen Y, Garber E, Zhao Q, et al. In vitro activity of doripenem (S-4661) against multidrug-resistant gram-negative bacilli isolated from patients with cystic fibrosis. Antimicrob Agents Chemother. 2005;49:2510-2511.
38. Aranza-Torres MK, Pillar CM, Shah D, Sahm D. Stratified analysis of doripenem activity against Enterobacteriaceae and Pseudomonas aeruginosa according to patient location: Inpatients and ICU patients. Presented at: 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); September 17-20, 2007; Chicago, IL.
39. Huynh HK, Biedenbach DJ, Jones RN. Delayed resistance selection for doripenem when passaging Pseudomonas aeruginosa isolates with doripenem plus an aminoglycoside. Diagn Microbiol Infect Dis. 2006;55:241-243.
40. Malafaia O, Umeh O, Jiang J. Doripenem versus meropenem for the treatment of complicated intraabdominal infections. Paper presented at: 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); September 27-30, 2006; San Francisco, CA.
41. Horiuchi M, Kimura M, Tokumura M, Hasebe N, Arai T, Abe K. Absence of convulsive liability of doripenem, a new carbapenem antibiotic, in comparison with beta-lactam antibiotics. Toxicology. 2006;222:114-124.
42. Nakajima Y, Mizobuchi M, Nakamura M, et al. Mechanism of the drug interaction between valproic acid and carbapenem antibiotics in monkeys and rats. Drug Metab Dispos. 2004;32:1383-1391.
43. Kobayashi Y. Study of the synergism between carbapenems and vancomycin or teicoplanin against MRSA, focusing on S-4661, a carbapenem newly developed in Japan. J Infect Chemother. 2005;11:259-261.
44. Mushtaq S, Warner M, Ge Y, Kaniga K, Livermore DM. In-vitro interactions of doripenem with other antibacterial agents. Presented at: 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); December 16-19, 2005; Washington, DC.
45. Psathas PA, Kuzmission A, Ikeda K, Yasuo S. Stability of doripenem for injection (500 mg) in representative infusion fluids and containers. Presented at: 2007 American Society of Health-System Pharmacists Summer Meeting; June 24-27, 2007; San Francisco, CA.
46. AmerisourceBergen website. http://www.amerisourcebergen.com. Accessed November 29, 2007.